共 11 条
- [1] PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroadsJOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (05) : 714 - 720Annemans, LievenStock, Jane K.Chapman, John
- [2] ONLY THIRTY PERCENT (30%) OF PATIENTS ON PCSK9 INHIBITORS ACHIEVE ESC/EAS LDL-CHOLESTEROL GUIDELINE TREATMENT TARGETS IN A LIPID CLINIC: REAL WORLD DATAATHEROSCLEROSIS, 2023, 379 : S65 - S65Bolodeoku, J.Morris, K.Whitehead, S.
- [3] Modeling lipid-lowering therapy intensification in the real world: how many patients with atherosclerotic cardiovascular disease would need a PCSK9 inhibitor?EUROPEAN HEART JOURNAL, 2016, 37 : 1014 - 1014Khan, I.Cannon, C. P.Klimchak, A.Reynolds, M. R.Sanchez, R. J.Sasiela, W. J.
- [4] IMPACT OF STATIN INTOLERANCE RATES ON NEED FOR EZETIMIBE AND/OR PCSK9 INHIBITORS FOR MEETING LOW-DENSITY LIPOPROTEIN GOALS IN A REAL-WORLD COHORT WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASEJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1663 - 1663Cannon, Christopher P.Khan, IrfanKlimchak, AlexaSanchez, RobertSasiela, WilliamReynolds, Matthew
- [5] Potential use of PCSK9 inhibitors as a secondary preventative measure for cardiovascular disease following acute coronary syndrome: a UK real-world studyPOSTGRADUATE MEDICAL JOURNAL, 2019, 95 (1120) : 61 - 66Elamin, Ahmed Farouk MohamedGrafton-Clarke, CiaranChen, Kai WenObafemi, TobaLuvai, AhaiKatira, RavishDavis, Gershan
- [6] Applying the FOURIER Trial amongst Real-world Cardiovascular Disease Patients: The Cardiovascular Health in Ambulatory Care Research Team (CANHEART) PCSK9 StudyCIRCULATION, 2017, 136Ko, Dennis T.Khan, Anam M.Kotrri, GynterKoh, MariaChu, AnnaAustin, Peter C.Wijeysundera, Harindra C.Tu, Jack V.
- [7] Impact of high neutrophil-to-lymphocyte ratio on the cardiovascular benefit of PCSK9 inhibitors in familial hypercholesterolemia subjects with atherosclerotic cardiovascular disease: Real-world data from two lipid unitsNUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2021, 31 (12) : 3401 - 3406Scicali, RobertoMandraf, GiuseppeDi Pino, AntoninoScuruchi, MicheleFerrara, VivianaSquadrito, GiovanniPurrello, FrancescoPiro, Salvatore
- [8] Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China(RWE-PCSK study)Journal of Geriatric Cardiology, 2021, 18 (04) : 261 - 270Yu-Qi LIUDan-Dan LIMeng CHAIHong-Liang CONGXiao-Qiang CONGJun DAIRong-Pin DUMing GAOJin-Cheng GUOYan-Qing GUOXiao-Jian HONGRong-Chong HUANGFeng-Shun JIAJia-Yu LIQing LIJia-Mei LIUXin-Ping LIUYu-Guo LIUHong-Gang NIEBing SHAOXiao-Yu SHENHai-Qing SONGYi-Jun SONGLi-Jun WANGShuo WANGDong-Mei WUJing XIAZhi-Yong YANGHong-Ying YUHui ZHANGTie-Mei ZHANGJi-Yi ZHAOLiang-Chen ZHAOMing-Qi ZHENGYun-Dai CHEN
- [9] Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study)JOURNAL OF GERIATRIC CARDIOLOGY, 2021, 18 (04) : 261 - 270Liu, Yu-QiLi, Dan-DanChai, MengCong, Hong-LiangCong, Xiao-QiangDai, JunDu, Rong-PinGao, MingGuo, Jin-ChengGuo, Yan-QingHong, Xiao-JianHuang, Rong-ChongJia, Feng-ShunLi, Jia-YuLi, QingLiu, Jia-MeiLiu, Xin-PingLiu, Yu-GuoNie, Hong-GangShao, BingShen, Xiao-YuSong, Hai-QingSong, Yi-JunWang, Li-JunWang, ShuoWu, Dong-MeiXia, JingYang, Zhi-YongYu, Hong-YingZhang, HuiZhang, Tie-MeiZhao, Ji-YiZhao, Liang-ChenZheng, Ming-QiChen, Yun-Dai
- [10] Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid UnitsBIOMEDICINES, 2022, 10 (07)Scicali, RobertoMandraffino, GiuseppeScuruchi, MicheleLo Gullo, AlbertoDi Pino, AntoninoFerrara, VivianaMorace, CarmelaAragona, Caterina OrianaSquadrito, GiovanniPurrello, FrancescoPiro, Salvatore